Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (8.999.813 €): Entwicklung einer robusten und innovativen Impfstoffwirksamkeit Hor 01.07.2017 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Entwicklung einer robusten und innovativen Impfstoffwirksamkeit
Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others. The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration. To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes. A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable. Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Abbott Biologicals B.V. | 0,00 € |
| Assistance Publique Hopitaux de Paris | 0,00 € |
| Association Internationale de Standardisation Biologique Pour l'Europe(Iabs-EU) | 343.438 € |
| Fundacion para El Fomento de La Investigacion Sanitaria y Biomedica de La Comunitat Valenciana | 3.904.659 € |
| Glaxosmithkline Biologicals SA | 0,00 € |
| Institut de Recherche Pour le Developpement | 89.591 € |
| Institut National de la Sante et de la Recherche Medicale | 1.453.491 € |
| Istituto Superiore Di Sanita | 211.048 € |
| Meningitis Research Foundation | 101.456 € |
| Ospedale Pediatrico Bambino Gesu | 321.452 € |
| P95 | 674.315 € |
| Sanofi R&D Vaccins | 0,00 € |
| Seqirus UK Ltd. | 0,00 € |
| Synapse Research Management Partners SL | 393.750 € |
| Terveyden JA Hyvinvoinnin Laitos | 349.250 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 262.972 € |
| Universita Degli Studi Di Firenze | 350.813 € |
| Universite Lyon 1 Claude Bernard | 315.250 € |
| University of Surrey | 228.329 € |
Quelle: https://cordis.europa.eu/project/id/777363
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.